Who can use Vabysmo(Faricimab-svoa)?

VABYSMO is approved for neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.

Approved Uses

VABYSMO is indicated for treating neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema after retinal vein occlusion (RVO). These conditions involve abnormal fluid accumulation or blood vessel growth in the retina, leading to vision loss. The drug addresses these issues by blocking key pathways involved in disease progression.